Mylan received license from Gilead for commercialisation of Remdesivir
Mylan today announced the commercial launch of its Remdesivir under the brand name DESREM in India to address urgent, unmet needs amid the evolving COVID-19 pandemic. The drug is approved for the treatment of suspected or laboratory confirmed incidences of COVID-19 in adults and children hospitalised with severe presentations of the disease. The company also launched a 24/7 helpline where patients and healthcare practitioners can access information about Mylan’s Remdesivir and its availability.
Mylan released the first batch of its generic Remdesivir (DESREM) and will continue to increase its supply across the country in the wake of the rising demand for the drug. Patients and healthcare practitioners can access information about the availability of DESREM in India through Mylan’s 24/7 national helpline number, +91.78299.80066.
Mylan will manufacture DESREM in its state-of-the-art injectable facility in Bengaluru, which will work to service the demand in India and other export markets where Mylan has received a license from Gilead for the commercialisation of Remdesivir.
Rakesh Bamzai, President, India and Emerging Markets, Mylan said: “In the wake of increasing cases of COVID-19 across India, Mylan remains committed to continue its efforts in the fight against the pandemic. With the launch of DESREM and our national 24/7 COVID-19 helpline, we aim to enhance access to this critical medicine, used for treating adults and children with severe presentations of COVID-19. At Mylan, we believe we have a responsibility to help make the world a better place and the entire team at Mylan has stepped up in this time of need to serve patients and deliver better health for a better world.”